Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.51 |
| ▸ | DRD2 | P14416 | 14/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593079 | 0.97 | DRD2 (0.51) | DRD3DRD2DRD4 | |
| SCHEMBL6778447 | 0.89 | DRD2 (0.62) | DRD3DRD2DRD4 | |
| SCHEMBL6598258 | 0.88 | DRD3 (0.49) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL6775702 | 0.87 | DRD3 (0.46) | DRD3DRD2HTR1DHTR1B | |
| SCHEMBL7535696 | 0.87 | DRD2 (0.49) | DRD3DRD2DRD4 | |
| SCHEMBL6597455 | 0.86 | DRD3 (0.51) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL6597012 | 0.86 | DRD3 (0.50) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL6595225 | 0.85 | DRD3 (0.51) | DRD3DRD2DRD4 | |
| SCHEMBL6594873 | 0.85 | DRD3 (0.51) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL6596564 | 0.84 | ALDH1A1 (0.48) | DRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818645-B2 | 2-AMINO-TRIHYDROINDOLE OR TETRAHYDRONAPTHALENE-2-YL DERIVATIVES, USEFUL FOR DISEASE STATE ASSOCIATED WITH SMOOTH MUSCLE DISORDERS, SUCH AS GASTROINTESTINAL AND UROGENITAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1289964-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| US-20040034018-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | WEIKERT ROBERT JAMES (US) | 2004-02-19 | — | — | US | disclosed |
| US-6645958-B2 | Oxazepine derivatives; urogenital, gastrointestinal, and respiratory system disorders; antiasthmatic and antiallergen agents | SYNTEX (U.S.A.) LLC | 2003-11-11 | — | — | US | disclosed |
| US-20030109524-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | WEIKERT ROBERT JAMES (US) | 2003-06-12 | — | — | US | disclosed |
| US-6500822-B2 | MUSCULAR DISORDERS, GASTROINTESTINAL DISORDERS, RESPIRATORY SYSTEM DISORDERS | SYNTEX (U.S.A.) LLC | 2002-12-31 | — | — | US | disclosed |
| US-20020004494-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004494-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | DRD3 278/4885DRD2 235/4885DRD4 267/4885 |
| US-20030109524-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | DRD3 278/4885DRD2 235/4885DRD4 267/4885 |
| US-20040034018-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | DRD3 278/4885DRD2 235/4885DRD4 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.